Ronald J. Biediger, PhD
Biediger é atualmente Diretor de Química Medicinal, Laboratórios de Pesquisa em Cardiologia Molecular no Texas Heart Institute, Houston, Texas, onde lidera um grupo de químicos que desenvolvem antagonistas e agonistas de integrinas de pequenas moléculas para uso como terapias ou como adjuvantes de terapias baseadas em células. , para doenças cardíacas, pulmonares e vasculares.
Mostrar bio completoDr. Biediger e sua equipe também estão desenvolvendo agentes direcionados para imagens de placas ateroscleróticas vulneráveis. Dr. Biediger obteve bacharelado em Matemática e Química pela Texas Lutheran College, seguido de doutorado em Química Orgânica pela Texas Tech University. Durante uma bolsa de pós-doutorado na Florida State University, fez parte da equipe que concluiu a primeira síntese total do Taxol sob a direção de Robert Holton. Antes de seu cargo atual no Texas Heart Institute, o Dr. Biediger foi Diretor Sênior de Química Medicinal na Encysive Pharmaceuticals, onde dirigiu vários projetos de descoberta e desenvolvimento de medicamentos ao longo de quatorze anos. Esses projetos resultaram em quatro novas entidades químicas que entraram em testes em humanos (incluindo o antagonista VLA-4 TBC4746) e uma outra que foi selecionada como candidata pré-clínica.
Ocultar biografia completa
Cargos do Texas Heart Institute
- Investigador Sênior e Diretor, MCRL-Química, Pesquisa em Cardiologia Molecular
Educação
-
graduação:
Faculdade Luterana do Texas
-
Pós-Graduação:
Texas Tech University
-
Bolsas de estudo:
Universidade Estadual da Flórida
Honras, prêmios e associações
- Prêmio Presidencial de Biotecnologia do Texas (2000)
- Equipe Profissional Acadêmica do Texas Heart Institute
Publicações
4862227
6MADD4J5
1
alternativas à experimentação animal
10
dados
desc
Biediger
1035
https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22I7XSBSGG%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hickman%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHickman%2C%20A.%2C%20Koetsier%2C%20J.%2C%20Kurtanich%2C%20T.%20et%20al.%20%282022%29.%20LFA-1%20activation%20enriches%20tumor-specific%20T%20cells%20in%20a%20cold%20tumor%20model%20and%20synergizes%20with%20CTLA-4%20blockade.%20%26lt%3Bi%26gt%3BJ%20Clin%20Invest%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B132%26lt%3B%5C%2Fi%26gt%3B%2C%20e154152.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1172%5C%2FJCI154152%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1172%5C%2FJCI154152%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22LFA-1%20activation%20enriches%20tumor-specific%20T%20cells%20in%20a%20cold%20tumor%20model%20and%20synergizes%20with%20CTLA-4%20blockade%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amber%22%2C%22lastName%22%3A%22Hickman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joost%22%2C%22lastName%22%3A%22Koetsier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Trevin%22%2C%22lastName%22%3A%22Kurtanich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20C.%22%2C%22lastName%22%3A%22Nielsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Glenn%22%2C%22lastName%22%3A%22Winn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yunfei%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salah-Eddine%22%2C%22lastName%22%3A%22Bentebibel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leilei%22%2C%22lastName%22%3A%22Shi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Punt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leila%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cara%22%2C%22lastName%22%3A%22Haymaker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20B.%22%2C%22lastName%22%3A%22Chesson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faisal%22%2C%22lastName%22%3A%22Fa%27ak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%20L.%22%2C%22lastName%22%3A%22Dominguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isere%22%2C%22lastName%22%3A%22Kuiatse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20R.%22%2C%22lastName%22%3A%22Caivano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sayadeth%22%2C%22lastName%22%3A%22Khounlo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Navin%20D.%22%2C%22lastName%22%3A%22Warier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Upendra%22%2C%22lastName%22%3A%22Marathi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20V.%22%2C%22lastName%22%3A%22Market%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20J.%22%2C%22lastName%22%3A%22Biediger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20W.%22%2C%22lastName%22%3A%22Craft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Hwu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20G.%22%2C%22lastName%22%3A%22Woodside%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vanderslice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adi%22%2C%22lastName%22%3A%22Diab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Willem%20W.%22%2C%22lastName%22%3A%22Overwijk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yared%22%2C%22lastName%22%3A%22Hailemichael%22%7D%5D%2C%22abstractNote%22%3A%22The%20inability%20of%20CD8%2B%20effector%20T%20cells%20%28Teffs%29%20to%20reach%20tumor%20cells%20is%20an%20important%20aspect%20of%20tumor%20resistance%20to%20cancer%20immunotherapy.%20The%20recruitment%20of%20these%20cells%20to%20the%20tumor%20microenvironment%20%28TME%29%20is%20regulated%20by%20integrins%2C%20a%20family%20of%20adhesion%20molecules%20that%20are%20expressed%20on%20T%20cells.%20Here%2C%20we%20show%20that%207HP349%2C%20a%20small-molecule%20activator%20of%20lymphocyte%20function-associated%20antigen-1%20%28LFA-1%29%20and%20very%20late%20activation%20antigen-4%20%28VLA-4%29%20integrin%20cell-adhesion%20receptors%2C%20facilitated%20the%20preferential%20localization%20of%20tumor-specific%20T%20cells%20to%20the%20tumor%20and%20improved%20antitumor%20response.%207HP349%20monotherapy%20had%20modest%20effects%20on%20anti-programmed%20death%201-resistant%20%28anti-PD-1-resistant%29%20tumors%2C%20whereas%20combinatorial%20treatment%20with%20anti-cytotoxic%20T%20lymphocyte-associated%20protein%204%20%28anti-CTLA-4%29%20increased%20CD8%2B%20Teff%20intratumoral%20sequestration%20and%20synergized%20in%20cooperation%20with%20neutrophils%20in%20inducing%20cancer%20regression.%207HP349%20intratumoral%20CD8%2B%20Teff%20enrichment%20activity%20depended%20on%20CXCL12.%20We%20analyzed%20gene%20expression%20profiles%20using%20RNA%20from%20baseline%20and%20on%20treatment%20tumor%20samples%20of%2014%20melanoma%20patients.%20We%20identified%20baseline%20CXCL12%20gene%20expression%20as%20possibly%20improving%20the%20likelihood%20or%20response%20to%20anti-CTLA-4%20therapies.%20Our%20results%20provide%20a%20proof-of-principle%20demonstration%20that%20LFA-1%20activation%20could%20convert%20a%20T%20cell-exclusionary%20TME%20to%20a%20T%20cell-enriched%20TME%20through%20mechanisms%20involving%20cooperation%20with%20innate%20immune%20cells.%22%2C%22date%22%3A%22July%2001%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1172%5C%2FJCI154152%22%2C%22ISSN%22%3A%221558-8238%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226MADD4J5%22%2C%22BBMMGS3D%22%2C%227XFQVVGN%22%2C%224R4R39JD%22%2C%227STYFUFZ%22%2C%225QIRWFUY%22%2C%22TC3LQMP8%22%2C%222RCWVZ4F%22%5D%2C%22dateModified%22%3A%222022-08-02T14%3A41%3A07Z%22%7D%7D%2C%7B%22key%22%3A%227TUX9HBZ%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lokugamage%20et%20al.%22%2C%22parsedDate%22%3A%222021-09-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLokugamage%2C%20N.%2C%20Chowdhury%2C%20I.%20H.%2C%20%26lt%3Bstrong%26gt%3BBiediger%26lt%3B%5C%2Fstrong%26gt%3B%2C%20R.%20J.%20et%20al.%20%282021%29.%20Use%20of%20a%20small%20molecule%20integrin%20activator%20as%20a%20systemically%20administered%20vaccine%20adjuvant%20in%20controlling%20Chagas%20disease.%20%26lt%3Bi%26gt%3BNPJ%20Vaccines%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B6%26lt%3B%5C%2Fi%26gt%3B%2C%20114.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41541-021-00378-5%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41541-021-00378-5%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Use%20of%20a%20small%20molecule%20integrin%20activator%20as%20a%20systemically%20administered%20vaccine%20adjuvant%20in%20controlling%20Chagas%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nandadeva%22%2C%22lastName%22%3A%22Lokugamage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Imran%20H.%22%2C%22lastName%22%3A%22Chowdhury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20J.%22%2C%22lastName%22%3A%22Biediger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20V.%22%2C%22lastName%22%3A%22Market%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sayadeth%22%2C%22lastName%22%3A%22Khounlo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Navin%20D.%22%2C%22lastName%22%3A%22Warier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shen-An%22%2C%22lastName%22%3A%22Hwang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20K.%22%2C%22lastName%22%3A%22Actor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20G.%22%2C%22lastName%22%3A%22Woodside%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Upendra%22%2C%22lastName%22%3A%22Marathi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vanderslice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nisha%20Jain%22%2C%22lastName%22%3A%22Garg%22%7D%5D%2C%22abstractNote%22%3A%22The%20development%20of%20suitable%20safe%20adjuvants%20to%20enhance%20appropriate%20antigen-driven%20immune%20responses%20remains%20a%20challenge.%20Here%20we%20describe%20the%20adjuvant%20properties%20of%20a%20small%20molecule%20activator%20of%20the%20integrins%20%5Cu03b1L%5Cu03b22%20and%20%5Cu03b14%5Cu03b21%2C%20named%207HP349%2C%20which%20can%20be%20safely%20delivered%20systemically%20independent%20of%20antigen.%207HP349%20directly%20activates%20integrin%20cell%20adhesion%20receptors%20crucial%20for%20the%20generation%20of%20an%20immune%20response.%20When%20delivered%20systemically%20in%20a%20model%20of%20Chagas%20disease%20following%20immunization%20with%20a%20DNA%20subunit%20vaccine%20encoding%20candidate%20T.%20cruzi%20antigens%2C%20TcG2%20and%20TcG4%2C%207HP349%20enhanced%20the%20vaccine%20efficacy%20in%20both%20prophylactic%20and%20therapeutic%20settings.%20In%20a%20prophylactic%20setting%2C%20mice%20immunized%20with%207HP349%20adjuvanted%20vaccine%20exhibited%20significantly%20improved%20control%20of%20acute%20parasite%20burden%20in%20cardiac%20and%20skeletal%20muscle%20as%20compared%20to%20vaccination%20alone.%20When%20administered%20with%20vaccine%20therapeutically%2C%20parasite%20burden%20was%20again%20decreased%2C%20with%20the%20greatest%20adjuvant%20effect%20of%207HP349%20being%20noted%20in%20skeletal%20muscle.%20In%20both%20settings%2C%20adjuvantation%20with%207HP349%20was%20effective%20in%20decreasing%20pathological%20inflammatory%20infiltrate%2C%20improving%20the%20integrity%20of%20tissue%2C%20and%20controlling%20tissue%20fibrosis%20in%20the%20heart%20and%20skeletal%20muscle%20of%20acutely%20and%20chronically%20infected%20Chagas%20mice.%20The%20positive%20effects%20correlated%20with%20increased%20splenic%20frequencies%20of%20CD8%2BT%20effector%20cells%20and%20an%20increase%20in%20the%20production%20of%20IFN-%5Cu03b3%20and%20cytolytic%20molecules%20%28perforin%20and%20granzyme%29%20by%20the%20CD4%2B%20and%20CD8%2B%20effector%20and%20central%20memory%20subsets%20in%20response%20to%20challenge%20infection.%20This%20demonstrates%20that%207HP349%20can%20serve%20as%20a%20systemically%20administered%20adjuvant%20to%20enhance%20T%20cell-mediated%20immune%20responses%20to%20vaccines.%20This%20approach%20could%20be%20applied%20to%20numerous%20vaccines%20with%20no%20reformulation%20of%20existing%20stockpiles.%22%2C%22date%22%3A%22Sept%2008%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41541-021-00378-5%22%2C%22ISSN%22%3A%222059-0105%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226MADD4J5%22%2C%22BBMMGS3D%22%2C%227XFQVVGN%22%2C%227STYFUFZ%22%2C%225QIRWFUY%22%2C%22TC3LQMP8%22%5D%2C%22dateModified%22%3A%222021-10-07T18%3A11%3A58Z%22%7D%7D%2C%7B%22key%22%3A%229LRIQ9XJ%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Woodside%20et%20al.%22%2C%22parsedDate%22%3A%222018-02-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWoodside%2C%20D.%20G.%2C%20Tanifum%2C%20E.%20A.%2C%20Ghaghada%2C%20K.%20B.%20et%20al.%20%282018%29.%20Magnetic%20resonance%20imaging%20of%20atherosclerotic%20plaque%20at%20clinically%20relevant%20field%20strengths%20%281T%29%20by%20targeting%20the%20integrin%20%26%23x3B1%3B4%26%23x3B2%3B1.%20%26lt%3Bi%26gt%3BSci%20Rep%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B8%26lt%3B%5C%2Fi%26gt%3B%2C%203733.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-018-21893-x%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-018-21893-x%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Magnetic%20resonance%20imaging%20of%20atherosclerotic%20plaque%20at%20clinically%20relevant%20field%20strengths%20%281T%29%20by%20targeting%20the%20integrin%20%5Cu03b14%5Cu03b21%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20G.%22%2C%22lastName%22%3A%22Woodside%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%20A.%22%2C%22lastName%22%3A%22Tanifum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ketan%20B.%22%2C%22lastName%22%3A%22Ghaghada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20J.%22%2C%22lastName%22%3A%22Biediger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20R.%22%2C%22lastName%22%3A%22Caivano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zbigniew%20A.%22%2C%22lastName%22%3A%22Starosolski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sayadeth%22%2C%22lastName%22%3A%22Khounlo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saakshi%22%2C%22lastName%22%3A%22Bhayana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahrzad%22%2C%22lastName%22%3A%22Abbasi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20W.%22%2C%22lastName%22%3A%22Craft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20S.%22%2C%22lastName%22%3A%22Maxwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chandreshkumar%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Igor%20V.%22%2C%22lastName%22%3A%22Stupin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deenadayalan%22%2C%22lastName%22%3A%22Bakthavatsalam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20V.%22%2C%22lastName%22%3A%22Market%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20T.%22%2C%22lastName%22%3A%22Willerson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vanderslice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ananth%20V.%22%2C%22lastName%22%3A%22Annapragada%22%7D%5D%2C%22abstractNote%22%3A%22Inflammation%20drives%20the%20degradation%20of%20atherosclerotic%20plaque%2C%20yet%20there%20are%20no%20non-invasive%20techniques%20available%20for%20imaging%20overall%20inflammation%20in%20atherosclerotic%20plaques%2C%20especially%20in%20the%20coronary%20arteries.%20To%20address%20this%2C%20we%20have%20developed%20a%20clinically%20relevant%20system%20to%20image%20overall%20inflammatory%20cell%20burden%20in%20plaque.%20Here%2C%20we%20describe%20a%20targeted%20contrast%20agent%20%28THI0567-targeted%20liposomal-Gd%29%20that%20is%20suitable%20for%20magnetic%20resonance%20%28MR%29%20imaging%20and%20binds%20with%20high%20affinity%20and%20selectivity%20to%20the%20integrin%20%5Cu03b14%5Cu03b21%28very%20late%20antigen-4%2C%20VLA-4%29%2C%20a%20key%20integrin%20involved%20in%20recruiting%20inflammatory%20cells%20to%20atherosclerotic%20plaques.%20This%20liposomal%20contrast%20agent%20has%20a%20high%20T1%20relaxivity%20%28~2%5Cu2009%5Cu00d7%5Cu2009105%5Cu2009mM-1s-1%20on%20a%20particle%20basis%29%20resulting%20in%20the%20ability%20to%20image%20liposomes%20at%20a%20clinically%20relevant%20MR%20field%20strength.%20We%20were%20able%20to%20visualize%20atherosclerotic%20plaques%20in%20various%20regions%20of%20the%20aorta%20in%20atherosclerosis-prone%20ApoE-%5C%2F-%20mice%20on%20a%201%20Tesla%20small%20animal%20MRI%20scanner.%20These%20enhanced%20signals%20corresponded%20to%20the%20accumulation%20of%20monocyte%5C%2Fmacrophages%20in%20the%20subendothelial%20layer%20of%20atherosclerotic%20plaques%20in%20vivo%2C%20whereas%20non-targeted%20liposomal%20nanoparticles%20did%20not%20demonstrate%20comparable%20signal%20enhancement.%20An%20inflammatory%20cell-targeted%20method%20that%20has%20the%20specificity%20and%20sensitivity%20to%20measure%20the%20inflammatory%20burden%20of%20a%20plaque%20could%20be%20used%20to%20noninvasively%20identify%20patients%20at%20risk%20of%20an%20acute%20ischemic%20event.%22%2C%22date%22%3A%22Feb%2027%2C%202018%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-018-21893-x%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NNUFWYNJ%22%2C%226MADD4J5%22%2C%22WGZKEVDQ%22%2C%22BBMMGS3D%22%2C%227XFQVVGN%22%2C%22JH9V95Q8%22%2C%22VXDM6BAE%22%2C%224R4R39JD%22%2C%227STYFUFZ%22%2C%225QIRWFUY%22%5D%2C%22dateModified%22%3A%222018-05-07T19%3A32%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22UPWYVR4P%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hsieh%20et%20al.%22%2C%22parsedDate%22%3A%222014-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHsieh%2C%20Y.%20T.%2C%20Gang%2C%20E.%20J.%2C%20Shishido%2C%20S.%20N.%20et%20al.%20%282014%29.%20Effects%20of%20the%20small-molecule%20inhibitor%20of%20integrin%20%26%23x3B1%3B4%2C%20TBC3486%2C%20on%20pre-B-ALL%20cells.%20%26lt%3Bi%26gt%3BLeukemia%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B28%26lt%3B%5C%2Fi%26gt%3B%2C%202101%26%23x2013%3B2104.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fleu.2014.182%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fleu.2014.182%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effects%20of%20the%20small-molecule%20inhibitor%20of%20integrin%20%5Cu03b14%2C%20TBC3486%2C%20on%20pre-B-ALL%20cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20T.%22%2C%22lastName%22%3A%22Hsieh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20J.%22%2C%22lastName%22%3A%22Gang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20N.%22%2C%22lastName%22%3A%22Shishido%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20N.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Khazal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Osborne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z.%20A.%22%2C%22lastName%22%3A%22Esguerra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Kwok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Jang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Bonig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20J.%22%2C%22lastName%22%3A%22Biediger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Vanderslice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20M.%22%2C%22lastName%22%3A%22Kim%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Oct%202014%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fleu.2014.182%22%2C%22ISSN%22%3A%221476-5551%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226MADD4J5%22%2C%22BBMMGS3D%22%5D%2C%22dateModified%22%3A%222018-05-02T20%3A35%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22NFZGT9TW%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vanderslice%20et%20al.%22%2C%22parsedDate%22%3A%222013-07-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVanderslice%2C%20P.%2C%20%26lt%3Bstrong%26gt%3BBiediger%26lt%3B%5C%2Fstrong%26gt%3B%2C%20R.%20J.%2C%20Woodside%2C%20D.%20G.%20et%20al.%20%282013%29.%20Small%20molecule%20agonist%20of%20very%20late%20antigen-4%20%28VLA-4%29%20integrin%20induces%20progenitor%20cell%20adhesion.%20%26lt%3Bi%26gt%3BJ%20Biol%20Chem%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B288%26lt%3B%5C%2Fi%26gt%3B%2C%2019414%26%23x2013%3B19428.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1074%5C%2Fjbc.M113.479634%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1074%5C%2Fjbc.M113.479634%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Small%20molecule%20agonist%20of%20very%20late%20antigen-4%20%28VLA-4%29%20integrin%20induces%20progenitor%20cell%20adhesion%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vanderslice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20J.%22%2C%22lastName%22%3A%22Biediger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20G.%22%2C%22lastName%22%3A%22Woodside%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wells%20S.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sayadeth%22%2C%22lastName%22%3A%22Khounlo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Navin%20D.%22%2C%22lastName%22%3A%22Warier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20William%22%2C%22lastName%22%3A%22Gundlach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20R.%22%2C%22lastName%22%3A%22Caivano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20G.%22%2C%22lastName%22%3A%22Bornmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20S.%22%2C%22lastName%22%3A%22Maxwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bradley%20W.%22%2C%22lastName%22%3A%22McIntyre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20T.%22%2C%22lastName%22%3A%22Willerson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%5D%2C%22abstractNote%22%3A%22Activation%20of%20the%20integrin%20family%20of%20cell%20adhesion%20receptors%20on%20progenitor%20cells%20may%20be%20a%20viable%20approach%20to%20enhance%20the%20effects%20of%20stem%20cell-based%20therapies%20by%20improving%20cell%20retention%20and%20engraftment.%20Here%2C%20we%20describe%20the%20synthesis%20and%20characterization%20of%20the%20first%20small%20molecule%20agonist%20identified%20for%20the%20integrin%20%5Cu03b14%5Cu03b21%20%28also%20known%20as%20very%20late%20antigen-4%20or%20VLA-4%29.%20The%20agonist%2C%20THI0019%2C%20was%20generated%20via%20two%20structural%20modifications%20to%20a%20previously%20identified%20%5Cu03b14%5Cu03b21%20antagonist.%20THI0019%20greatly%20enhanced%20the%20adhesion%20of%20cultured%20cell%20lines%20and%20primary%20progenitor%20cells%20to%20%5Cu03b14%5Cu03b21%20ligands%20VCAM-1%20and%20CS1%20under%20both%20static%20and%20flow%20conditions.%20Furthermore%2C%20THI0019%20facilitated%20the%20rolling%20and%20spreading%20of%20cells%20on%20VCAM-1%20and%20the%20migration%20of%20cells%20toward%20SDF-1%5Cu03b1.%20Molecular%20modeling%20predicted%20that%20the%20compound%20binds%20at%20the%20%5Cu03b1%5C%2F%5Cu03b2%20subunit%20interface%20overlapping%20the%20ligand-binding%20site%20thus%20indicating%20that%20the%20compound%20must%20be%20displaced%20upon%20ligand%20binding.%20In%20support%20of%20this%20model%2C%20an%20analog%20of%20THI0019%20modified%20to%20contain%20a%20photoreactive%20group%20was%20used%20to%20demonstrate%20that%20when%20cross-linked%20to%20the%20integrin%2C%20the%20compound%20behaves%20as%20an%20antagonist%20instead%20of%20an%20agonist.%20In%20addition%2C%20THI0019%20showed%20cross-reactivity%20with%20the%20related%20integrin%20%5Cu03b14%5Cu03b27%20as%20well%20as%20%5Cu03b15%5Cu03b21%20and%20%5Cu03b1L%5Cu03b22.%20When%20cross-linked%20to%20%5Cu03b1L%5Cu03b22%2C%20the%20photoreactive%20analog%20of%20THI0019%20remained%20an%20agonist%2C%20consistent%20with%20it%20binding%20at%20the%20%5Cu03b1%5C%2F%5Cu03b2%20subunit%20interface%20and%20not%20at%20the%20ligand-binding%20site%20in%20the%20inserted%20%28%26quot%3BI%26quot%3B%29%20domain%20of%20the%20%5Cu03b1L%20subunit.%20Co-administering%20progenitor%20cells%20with%20a%20compound%20such%20as%20THI0019%20may%20provide%20a%20mechanism%20for%20enhancing%20stem%20cell%20therapy.%22%2C%22date%22%3A%22Jul%2005%2C%202013%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1074%5C%2Fjbc.M113.479634%22%2C%22ISSN%22%3A%221083-351X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NNUFWYNJ%22%2C%226MADD4J5%22%2C%22WGZKEVDQ%22%2C%22BBMMGS3D%22%2C%227XFQVVGN%22%2C%224R4R39JD%22%2C%227STYFUFZ%22%2C%22TC3LQMP8%22%5D%2C%22dateModified%22%3A%222018-05-02T21%3A14%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22P3UTU8F7%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vanderslice%20et%20al.%22%2C%22parsedDate%22%3A%222004%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVanderslice%2C%20P.%2C%20%26lt%3Bstrong%26gt%3BBiediger%26lt%3B%5C%2Fstrong%26gt%3B%2C%20R.%20J.%2C%20Woodside%2C%20D.%20G.%20et%20al.%20%282004%29.%20Development%20of%20cell%20adhesion%20molecule%20antagonists%20as%20therapeutics%20for%20asthma%20and%20COPD.%20%26lt%3Bi%26gt%3BPulm%20Pharmacol%20Ther%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B17%26lt%3B%5C%2Fi%26gt%3B%2C%201%26%23x2013%3B10.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.pupt.2003.10.004%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.pupt.2003.10.004%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Development%20of%20cell%20adhesion%20molecule%20antagonists%20as%20therapeutics%20for%20asthma%20and%20COPD%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vanderslice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20J.%22%2C%22lastName%22%3A%22Biediger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20G.%22%2C%22lastName%22%3A%22Woodside%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kurt%20L.%22%2C%22lastName%22%3A%22Berens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%20W.%22%2C%22lastName%22%3A%22Holland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%5D%2C%22abstractNote%22%3A%22Airway%20inflammation%20is%20a%20hallmark%20of%20respiratory%20diseases%20such%20as%20asthma%20and%20chronic%20obstructive%20pulmonary%20disease.%20Cell%20adhesion%20molecules%20play%20critical%20roles%20in%20the%20recruitment%20and%20migration%20of%20cells%20to%20sites%20of%20inflammation.%20Not%20surprisingly%2C%20these%20receptors%20have%20garnered%20the%20attention%20of%20the%20pharmaceutical%20industry%20as%20targets%20for%20the%20development%20of%20drugs%20to%20treat%20inflammatory%20and%20autoimmune%20diseases.%20Although%20several%20potential%20cell%20adhesion%20targets%20exist%2C%20development%20of%20compounds%20for%20pulmonary%20indications%20has%20centered%20around%20the%20selectins%20and%20the%20integrin%20VLA-4.%20In%20vitro%20and%20in%20vivo%20studies%20have%20implicated%20these%20receptors%20in%20the%20recruitment%20of%20inflammatory%20cells%20to%20the%20lung%20as%20well%20as%20to%20key%20cellular%20activation%20pathways.%20Several%20first%20generation%20compounds%20are%20currently%20in%20clinical%20development%20for%20asthma.%20Positive%20data%20from%20a%20phase%20II%20clinical%20trial%20using%20an%20inhaled%20formulation%20of%20a%20selectin%20antagonist%20has%20recently%20been%20reported.%20Initial%20results%20from%20clinical%20trials%20using%20first%20generation%20VLA-4%20antagonists%20have%20been%20less%20promising%20but%20additional%20trials%20with%20more%20fully%20optimized%20compounds%20are%20underway.%20Results%20from%20these%20trials%20will%20provide%20insight%20into%20what%20the%20future%20holds%20for%20this%20exciting%20new%20class%20of%20drugs%20to%20treat%20pulmonary%20diseases.%22%2C%22date%22%3A%222004%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.pupt.2003.10.004%22%2C%22ISSN%22%3A%221094-5539%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226MADD4J5%22%2C%22BBMMGS3D%22%2C%227XFQVVGN%22%5D%2C%22dateModified%22%3A%222022-02-17T17%3A36%3A26Z%22%7D%7D%5D%7D
Hickman, A., Koetsier, J., Kurtanich, T. et al. (2022). A ativação de LFA-1 enriquece células T específicas de tumor em um modelo de tumor frio e sinergiza com o bloqueio de CTLA-4. J Clin Invest 132, E154152. https://doi.org/10.1172/JCI154152.
Lokugamage, N., Chowdhury, IH, Biediger, RJ et al. (2021). Uso de um ativador de integrina de molécula pequena como adjuvante de vacina administrado sistemicamente no controle da doença de Chagas. Vacinas NPJ 6 114. https://doi.org/10.1038/s41541-021-00378-5.
Woodside, DG, Tanifum, EA, Ghaghada, KB et al. (2018). Imagem de ressonância magnética da placa aterosclerótica em intensidades de campo clinicamente relevantes (1T), visando a integrina α4β1. Sci Rep 8 3733. https://doi.org/10.1038/s41598-018-21893-x.
Hsieh, YT, Gang, EJ, Shishido, SN et al. (2014). Efeitos do inibidor de molécula pequena da integrina α4, TBC3486, em células pré-B-ALL. Leucemia 282101-2104. https://doi.org/10.1038/leu.2014.182.
Vanderslice, P., Biediger, RJ, Woodside, DG et al. (2013). O agonista de moléculas pequenas da integrina do antígeno 4 muito tardio (VLA-4) induz a adesão das células progenitoras. J Biol Chem 28819414-19428. https://doi.org/10.1074/jbc.M113.479634.
Vanderslice, P., Biediger, RJ, Woodside, DG et al. (2004). Desenvolvimento de antagonistas de moléculas de adesão celular como terapêutica para asma e DPOC. Pulm Pharmacol Ther 171-10. https://doi.org/10.1016/j.pupt.2003.10.004.
Notícias recentes
O Texas Heart Institute colabora com a Aviara Pharmaceuticals, Inc. para desenvolver um novo medicamento para DII
HOUSTON (26 de setembro de 2023) — A Aviara Pharmaceuticals, Inc., por meio de uma colaboração de pesquisa com o Texas Heart Institute® (THI), foi recentemente...
NIH concede ao Texas Heart Institute US$ 1.14 milhão para desenvolver um medicamento novo e de primeira classe para doença cardiovascular aterosclerótica
HOUSTON (22 de agosto de 2023) — O National Heart, Lung, and Blood Institute (NHLBI) premiou recentemente o Texas Heart Institute® (THI)...
Investigadores do Texas Heart Institute recebem subsídio por meio do NHLBI Catalyze Program
Os pesquisadores de Cardiologia Molecular do Texas Heart Institute (THI) Peter Vanderslice, PhD, e Ronald J. Biediger, PhD, receberam recentemente uma bolsa da...
